Last updated 2026-08-22
Total raised
—
Stage
—
Founded
2006
Headcount
—
HQ
Ness-Ziona, Israel
Sector
Biotechnology
About
Our Approach. SymThera combines scientific insight with proprietary technology to rationally design drug leads that appropriately affect multiple targets with a single agent to provide a more robust impact on restoring health. SymThera's drug leads, biological peptides, address the immediate shortcomings of existing medication. SymThera believes that it occupies a unique niche in drug discovery by being the first company to exploit network theory to identify patterns of conserved functionality in groups of disease-associated proteins known to control disease-specific inflammation.
Q&A
- What is SymThera Ltd.'s primary focus?
- SymThera Ltd. is a drug discovery company focused on identifying novel treatments for autoimmune and inflammatory diseases with unmet medical needs.
- When was SymThera Ltd. founded?
- SymThera Ltd. was founded in 2006.
- Where is SymThera Ltd. headquartered?
- SymThera Ltd. is headquartered in Ness-Ziona, Israel.
- What is SymThera Ltd.'s core technology?
- SymThera Ltd. utilizes a proprietary drug discovery platform that combines scientific insight with technology to design drug leads affecting multiple targets with a single agent, specifically biological peptides.
- Which diseases does SymThera Ltd. target?
- SymThera Ltd. targets autoimmune diseases, inflammatory diseases, and metastatic cancer.
- Who is a key founder of SymThera Ltd.?
- Chai Ezerzer is a founder of SymThera Ltd. and serves as the Chief Science Officer.
Team · 1
Chai Ezerzer
Founder · Chief Science Officer
Sectors & technology
Primary sector
Biotechnology
Technologies
Business model
B2B
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | symthera.com |
|---|
Identifiers & details
| Founded | 2006 |
|---|